Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 9/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12923328 | 0.94 | PRSS1 (0.38) | SLC6A9PRSS1PRSS2PRSS3TSHR | |
| SCHEMBL980208 | 0.88 | SLC6A9 (0.35) | SLC6A9PRSS1PRSS2PRSS3TSHR | |
| SCHEMBL977640 | 0.86 | OPRM1 (0.38) | SLC6A9PRSS1PRSS2PRSS3TSHR | |
| SCHEMBL977848 | 0.84 | KMT2A (0.37) | TSHRALDH1A1KDM4E | |
| Trifluoroacetic Acid SCHEMBL979474 | 0.77 | ALDH1A1 (0.33) | PRSS1PRSS2PRSS3ALDH1A1KDM4E | |
| Trifluoroacetic Acid SCHEMBL978104 | 0.76 | ALDH1A1 (0.35) | PRSS1PRSS2PRSS3ALDH1A1KDM4E | |
| SCHEMBL12923331 | 0.75 | TAAR1 (0.36) | PRSS1PRSS2PRSS3ALDH1A1TAAR1 | |
| SCHEMBL12923305 | 0.74 | TAAR1 (0.39) | PRSS1PRSS2PRSS3HDAC1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL977959 | 0.73 | S1PR1 (0.47) | — | |
| Trifluoroacetic Acid SCHEMBL977799 | 0.72 | SPHK1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680282-B2 | Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-03-25 | — | — | US | disclosed |
| US-20110015174-A1 | CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015174-A1 | CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | SLC6A9 709/4885BACE1 2259/4885PRSS1 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.